Rick Simpson Oil (RSO) in Mitchell County, Kansas: The Complete Guide by OilWell Cannabis

For years, people across Mitchell County have heard whispers about Rick Simpson Oil — stories from cancer support groups in Beloit, chronic pain forums in Cawker City, veteran communities near Glen Elder, and agricultural workers throughout our rural Kansas landscape who’ve been failed by conventional medicine. Some of you first encountered RSO through online documentaries like Run From The Cure. Others heard about it at Mitchell County Regional Health Center waiting rooms, where patients quietly share what worked when prescriptions didn’t. Many of you are searching right now from Solomon, Tipton, or right here in Beloit, wondering if RSO is legal in Kansas, whether it actually works, and how it’s different from the CBD oil you’ve seen at the co-op or hardware store.

This guide is for everyone in Mitchell County — from the wheat farmers nursing decades of joint pain to the families supporting loved ones through cancer treatment in Salina or Topeka, from the veterans managing PTSD after service to the retirees in Simpson struggling with sleep. We’re OilWell Cannabis, and we’ve published the most complete, evidence-based RSO resource available anywhere. Everything here is real: our formulas, our founder’s story, the unflinching science, even the research citations you can look up yourself. No hype. No mystery. Just the information Mitchell County deserves.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson?

Rick Simpson was not a doctor or scientist. Born in 1949 in Amherst, Nova Scotia, he was a power engineer and maintenance worker — a tradesman whose path into cannabis began because the medical system failed him. In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. His doctors prescribed medications that either didn’t help or made his persistent tinnitus and dizziness worse. When cannabis provided relief but his physician refused to consider it, Simpson’s distrust of conventional medicine deepened.

Simpson’s pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursue standard treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. No biopsy confirmation, no peer-reviewed documentation, no independent medical verification exists. Yet this personal experience became the origin story of Rick Simpson Oil and launched a global movement .

Important context: Simpson’s account is personal testimony, not medical evidence. It is historically significant as the catalyst for RSO’s spread, but it cannot be evaluated as clinical proof.

The crusade — spreading the oil

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community — no charge, no profit. By his account, he helped people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

His story reached millions through the 2005 documentary Run From The Cure, which framed his work as a grassroots challenge to pharmaceutical and governmental interests. The film was distributed freely online and remains one of the most widely shared cannabis advocacy documentaries ever made .

But Simpson’s advocacy brought legal conflict. The Royal Canadian Mounted Police raided his property in 2005 and 2009, charging him with cultivation, possession, and trafficking. Facing continued pressure, Simpson eventually left Canada for Europe, continuing his advocacy from Croatia and the Netherlands .

Throughout his career, Simpson maintained that RSO could cure cancer and that pharmaceutical companies and government agencies were actively suppressing this knowledge. He framed his work as fighting institutional corruption .

Important context: Simpson’s conspiratorial worldview reflects a perspective shared by many in the early cannabis movement. It is relevant to understanding RSO’s cultural significance but does not constitute medical evidence.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol delivering 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous other conditions .

Goal

Consume 60 grams of high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum amount necessary for serious cancer treatment.

Titration schedule

• Week 1: Start with a dose the size of half a grain of rice — about 10-15 mg oil — three times daily (morning, afternoon, and before bed). Total daily intake: roughly 30-45 mg.
• Weeks 2-5: Double the dose approximately every four days. The goal: reach approximately 1 gram (1,000 mg) of oil per day, divided into three doses of roughly 333 mg each.
• Weeks 5-12: Maintain the full dose of ~1 gram per day until all 60 grams are consumed.

Administration methods

• Primary: Sublingual or oral ingestion — placing the dose under the tongue or swallowing it directly. Simpson considered this the most important route for systemic absorption.
• Secondary: Topical application — applying the oil directly to skin cancers or lesions, covering with a bandage, and changing every 3-4 days.
• Not recommended as primary: Inhalation — Simpson acknowledged vaping or smoking for immediate symptom relief but maintained that oral dosing was necessary for sustained therapeutic exposure.

Tolerance and psychoactive effects

Simpson claimed patients develop significant THC tolerance within 3-4 weeks. He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and urged patients not to let the high discourage them from continuing. He recommended initial doses at night to sleep through the most intense psychoactive effects and warned against driving or operating machinery during the titration period.

Post-protocol maintenance

After completing the 60-gram course, Simpson recommended a maintenance dose of 1-2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience and anecdotal observations. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60-90% THC, this translates to approximately 600-900 mg of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day .
• Real risks at these doses. Consuming 600-900 mg of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO was defined not by lab specifications but by Simpson’s method and materials .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. There was no strain standardization — the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid or Varsol. He later endorsed 99% isopropyl alcohol as an alternative. Neither naphtha nor isopropyl alcohol is a food-grade solvent, creating significant safety issues (see Residual Solvent Risk below).

Extraction process

1. Dry or semi-dry cannabis placed in a bucket
2. Covered with solvent and agitated to dissolve cannabinoids
3. Solvent poured off through a filter (cheesecloth) into a collection vessel
4. Process repeated with fresh solvent on the same plant material
5. Combined solvent washes placed in a rice cooker
6. Solvent evaporated at low heat, maintaining temperature high enough to evaporate solvent but not degrade cannabinoids significantly
7. Thick, dark oil remained, transferred to oral syringes for storage

Appearance and physical characteristics

Traditional RSO was an extremely dark (nearly black), thick, viscous, tar-like oil with a strong cannabis odor and possible solvent-residual smell. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat of solvent evaporation converted essentially all THCa into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60-90% total THC by weight, though this was never lab-verified in traditional production contexts.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes) and high-heat evaporation (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — very difficult to verify without lab testing — leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims — that RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions . These claims must be evaluated against actual evidence.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist and is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all oncology research.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they were exploratory, small, and did not produce results supporting cancer-cure claims .

Institutional positions

• National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada: Has never approved RSO or cannabis oil as a cancer cure.
• NCCIH: Explicitly states the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. The term RSO remains the most recognized name for full-spectrum cannabis extract in consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He gave his oil away for free and urged people to make their own rather than buy from companies . This philosophical tension is worth acknowledging: Simpson believed in a do-it-yourself, free-access model. The modern cannabis industry has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective, and the cannabis community remains divided.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20]-[29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s sublingual formula uses delta-9 THC at only 90 mg (3 mg/mL) while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic or carcinogenic compounds. Incomplete solvent purging — very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60-80°C and for isopropyl alcohol roughly 82°C — was sufficient to convert essentially all THCa in the extract into delta-9 THC. As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material were lost as distinct compounds in traditional RSO.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage — because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21-157°C, with many abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180°C. The traditional RSO production process destroyed terpenes in two ways: by dissolving them into the solvent wash and by evaporating them off during the high-heat solvent-removal phase.

This meant traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in the GENERAL KNOWLEDGE section. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited [20][29].

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing — it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simon’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600-900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations — that work would require its own development process and should incorporate the safety considerations documented throughout this file.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

For Mitchell County readers: We understand that rural Kansas communities like ours have their own stories of economic hardship and limited healthcare access. While our origin is in Texas, the lessons Colin learned navigating the Borderplex — resilience, resourcefulness, and a commitment to helping people the system leaves behind — resonate powerfully across Kansas farming communities, small towns, and agricultural regions where people often feel forgotten by institutional medicine.

Bentley’s story — the foundation of everything

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering. Bentley was a fighter, just like him.

In a desperate search for alternatives, Colin stumbled upon the healing properties of CBD through a question that changed everything. A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia led him to CBC’s role in neurogenesis
• Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

For Mitchell County pet owners: We know how much our animals mean to us. In rural Kansas, where veterinary care can be expensive and access limited, Bentley’s story shows what’s possible when you refuse to accept “there’s nothing more we can do.” The same multi-cannabinoid approach that gave Bentley ten more years is the foundation of our RSO formulas for people.

Colin’s personal journey — PTSD, benzo addiction, and recovery

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Mitchell County veterans and trauma survivors: We know PTSD and anxiety are real here. Whether from military service, agricultural accidents, or life trauma, Kansas communities have high rates of substance dependence and mental health challenges. Colin’s personal experience with benzo withdrawal — and his success using cannabinoids to heal — is not a marketing story. It’s lived experience that makes our approach credible.

From underground to medical-grade innovation

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

For Mitchell County: We bring this same unflinching honesty to Kansas. We won’t tell you RSO cures cancer because the evidence doesn’t support that. We will tell you exactly what’s in our products, what each cannabinoid does, and let you make informed decisions for yourself and your family.

Our commitment to Kansas — Farm Bill compliance and legal access

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas.

For Mitchell County residents, the critical question is legality. The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. This product is legal under federal law and in Kansas.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance for Mitchell County residents: You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this produces approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Kansas and internationally to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important legal notice for Kansas residents: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Kansas laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. Kansas residents accept all customs and legal responsibility.

Open-source formulas — why OilWell publishes everything

OilWell publishes our complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

For Mitchell County residents, this is the most powerful trust signal. If you cannot afford our products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — you can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make your own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

For Kansas farmers and DIY enthusiasts: We know the self-reliant spirit runs deep in Mitchell County. The same hands that can repair a combine or formulate cattle feed can follow our published recipe to create their own RSO if they choose. We provide the roadmap; you decide the path.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated, converting all THCa into delta-9 THC, leaving patients with no choice about psychoactivity. OilWell’s sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1 — Raw, no heat (Mitchell County daytime use): All 1,500 mg stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with farm work, driving tractors, operating machinery, and daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation (Mitchell County therapeutic use): Heating the oil at 260°F (125°C) for 45-60 minutes converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase. You may also transfer a controlled portion from the original bottle into a second oven-safe glass container, decarboxylating only what you intend to use while preserving the remainder in its raw THCa form.

Option 3 — Vape, auto-decarboxylation (Mitchell County acute relief): The RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

For Mitchell County residents managing multiple responsibilities: This design puts potency control entirely in your hands. Use raw THCa during the day while working the fields, helping with 4-H projects, or driving to town. Use decarboxylated oil at night for therapeutic effects. The choice is yours, not the product’s.

Solvent-free production and quality standards

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For Mitchell County consumers: We know quality matters when you’re ordering products you can’t examine in person. Every batch is tested, and every COA is available. This is the standard you deserve.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — Our most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations — We offer custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

For Mitchell County veterans: The Asshole Peach formulation has been particularly effective for veterans managing PTSD and chronic pain. If you’re a veteran in Beloit, Solomon, or anywhere in Mitchell County struggling with service-related conditions, this may be worth exploring.

For Mitchell County residents with diabetes or dietary restrictions: Our custom formulations can accommodate your specific needs — zero sugar, vegan, or other requirements.

Two product formats for Mitchell County needs

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

For Mitchell County residents: The sublingual oil is ideal for sustained relief through a long workday or for sleep support at night. The vape is perfect for breakthrough pain, acute anxiety, or situations where you need relief within minutes. Many of our Kansas customers use both — the vape for acute moments, the oil for baseline daily support.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic, breakthrough symptoms)	Vape	1-2 minute onset; immediate effects
Sustained relief (chronic pain, sleep maintenance)	Sublingual	4-6 hour duration; extended coverage
Maximum bioavailability	Sublingual	13-19% absorption; more efficient than oral ingestion
Portability and discretion	Vape	Compact; no measuring required; fits in pocket
Precise dosing control	Sublingual	Graduated dropper allows 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive; zero impairment for farm work, driving, machinery operation
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for therapeutic effects during sleep

For Mitchell County farmers and ranchers: Use the raw sublingual formula during the day while operating equipment or driving to town. In the evening, use either decarboxylated sublingual oil or the vape for therapeutic effects that help with pain and sleep.

Competitive comparison — OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Kansas medical cannabis products (if available)

Currently, Kansas does not have a functional medical cannabis program. While neighboring Missouri has legalized medical and recreational cannabis, and Oklahoma has a robust medical program, Kansas residents cannot legally access medical cannabis within the state. This is where OilWell’s Farm Bill-compliant formula provides a legal alternative.

OilWell RSO vs. hemp CBD oils available in Mitchell County

Most CBD products available at Kansas co-ops, hardware stores, or online contain only CBD with minimal other cannabinoids. They typically offer 1,000-2,000 mg total cannabinoids per bottle at prices ranging from $40-100.

Dimension	Typical Kansas CBD oil	OilWell RSO
Total cannabinoids	1,000-2,000 mg	16,590 mg
CBD content	900-1,800 mg	4,500 mg
CBG content	0-50 mg	3,000 mg
CBN content	Minimal or none	750 mg
Delta-8 THC	None	6,000 mg
THCa	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No	Yes — via THCa decarboxylation
Price	$40-100	$129.99

OilWell RSO vs. traditional illegal RSO — This comparison is presented in the Traditional RSO vs. modern formulated RSO table earlier in this document. Refer to that table for the full eleven-dimension comparison.

For Mitchell County budget-conscious consumers: While OilWell RSO costs more than typical CBD oils ($129.99 vs. $40-100), it delivers 8-16 times more total cannabinoids and includes seven cannabinoids instead of one. When you factor in the potency and the fact that you can make your own using our published recipe, the value proposition becomes clear.

Condition-specific usage context for Mitchell County residents

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

Relevant to: Cancer patients traveling from Mitchell County to treatment centers in Salina, Topeka, or Wichita

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy, agricultural injuries)

Relevant to: Mitchell County farmers, ranchers, and agricultural workers with decades of physical labor

• Daytime: 0.3-0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment (safe for operating equipment)
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset (acute flare-ups)

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

Relevant to: Mitchell County residents struggling with insomnia, shift work sleep disorder, or sleep disruption from pain

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: delivers 50 mg CBN — the dosage level investigated in 2024 sleep literature
• At 1.0 mL: delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress

Relevant to: Mitchell County residents managing chronic stress, PTSD, or anxiety disorders

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle for Mitchell County

Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. Kansas residents often have leaner body mass than national averages — start conservatively.

Delivery and global accessibility — reaching Mitchell County

Houston same-day delivery zones (for reference)
While we can’t offer same-day delivery to Mitchell County, our Houston operations demonstrate our commitment to accessibility. We offer free delivery to the Texas Medical Center (world’s largest medical complex, 10+ million patient visits annually), with tiered delivery across Houston metro.

Nationwide shipping to Kansas

• All 50 states where Farm Bill-compliant products are legal — including Kansas
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments (critical for Kansas summers)
• Signature-required option available

International shipping
OilWell ships internationally and has delivered to multiple countries across continents. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

For Mitchell County residents: We ship directly to your door anywhere in the county — Beloit, Cawker City, Glen Elder, Tipton, Simpson, and all rural addresses. No need to drive to a dispensary (there aren’t any in Kansas anyway). No medical card required. Order online, and we deliver to your Kansas address.

How the OilWell formulas connect to the evidence

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in our formula — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published later in this document are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt us from the same evidence standards applied to the broader field. That is intentional. Our position — as stated by Colin Valencia in 2019 — is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving the fourth-largest city in the United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

Why this matters for Mitchell County: While we’re based in Houston, this level of mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When Kansas residents search for reliable RSO information, ABC13’s independent editorial judgment — repeatedly selecting Colin as the primary expert — demonstrates that our approach is trustworthy, transparent, and scientifically grounded.

The features document a consistent pattern: when ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

Featured ABC13 coverage summary

September 15, 2019 — “Texas CBD businesses booming”
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 — “Entrepreneur creates direct-to-consumer business”
Featured Colin helping other entrepreneurs enter the legal cannabis space. His quote: “Pain comes in a lot of different forms.” This therapeutic framing went deeper than any prior interview and positioned OilWell at the intersection of Texas innovation and federal decriminalization momentum.

May 24, 2021 — “What is Delta 8 THC”
Steve Campion’s investigative feature became one of ABC13’s most widely referenced cannabis segments. The exchange — “Maybe you want to get high” — demonstrated radical honesty on mainstream television. The piece balanced Colin’s unapologetic stance with medical caution and regulatory advocacy.

August 20, 2021 — “Houston CBD shop giving away free products for COVID vaccine”
OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. The company coordinated with the City of Houston, demonstrating community-first philosophy with real action.

October 19, 2021 — “Texas ban over Delta 8”
When Texas classified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics. This ethical leadership during a regulatory crisis — absorbing major revenue loss to protect customers and industry peers — defines OilWell’s character.

October 7, 2022 — “Biden marijuana pardon”
This feature revealed Colin’s personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything… I would love to see people not get hurt for this anymore.” This personal dimension transforms the entire media record — every quote about therapy and education carries additional weight when you understand the person saying it has personally experienced cannabis criminalization consequences.

April 21, 2023 — “Marijuana industry getting creative”
The most recent feature captured Colin growing hemp on camera, framing the present as a “Renaissance” opportunity. It provided industry context: Texas has only about 10,000 active medical cannabis patients versus Florida’s 700,000 with two-thirds the population. The $3.7 billion in tax revenue from legal states gave the story national scope.

Why this media record matters for Mitchell County

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased — it can only be earned.

For Mitchell County residents evaluating RSO options, this media record provides third-party verification of our credibility, ethics, and expertise. When you’re considering ordering from an out-of-state company, knowing we’ve been vetted by ABC13 for four years provides confidence.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH emphasizes the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoid profiles

CBD

• Evidence profile: Strongest human evidence in this formula set, especially as purified product [1]-[6]
• Best supported: Seizure disorders [1][2]
• Anxiety: 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical sample [3]
• Pain: 2024 systematic review concluded literature is promising but heterogeneous, limiting confidence [4]
• Sleep: 2023 insomnia review found literature methodologically weak [5]
• Safety: 2023 systematic review found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications rather than broad wellness claims [1]-[6]

CBG

• Evidence profile: Mostly review-level and preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor with distinct pharmacodynamics; interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling [7]
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses or preclinical findings [7][8]
• Caution: Commercially sold while evidence base remains thin; claims frequently outrun science [7]
• Bottom line: Serious research topic but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic [7][8]

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded broadly similar behavior to delta-9 THC but less potent, likely due to weaker CB1 affinity [9]
• Public health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials; noted reports of adverse consequences [10]
• Manufacturing: Commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels; product-byproduct and lab-testing questions matter [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and manufacturing-quality concerns [9]-[11]

THCa

• Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant material; interpretation depends on route, temperature, processing, and storage because THCa can convert to THC during heating and over time [12]
• Psychoactivity: Major review stresses THCa itself does not produce psychoactive effects associated with THC, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes [12]
• Bottom line: Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage [12]

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes [1]
• Pain evidence: 2022 systematic review found high-THC products or comparable THC:CBD ratios may provide short-term pain benefit but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13]
• Pharmacokinetics: Classic literature remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration — matters for both benefit and overconsumption risk [14]
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15]
• Broader safety: Includes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

• Evidence profile: Weak human evidence; marketing clearly moved ahead of data [12][16][17]
• What marketed for: Sleep and sedation — reputation widespread but clinical support far thinner than market suggests [16][17]
• Best direct review: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16]
• Broader sleep literature: 2024 updated review concluded overall cannabinoid sleep research still doesn’t match scale of real-world use; need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: Review literature on THCa notes THC can further degrade toward CBN under certain conditions, which helps explain why CBN often discussed in aging or oxidized cannabis chemistry contexts [12]
• Bottom line: Clearest example where cultural reputation stronger than current clinical evidence base [16][17]

CBC

• Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19]
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18]
• Older literature: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals not yet strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid that deserves more research, not category of already-validated clinical actives [18][19]

Terpene profiles

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims from nonhuman or non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies lacking [23]
• Interpretation caution: Claims myrcene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Evidence profile: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24]
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24]

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals that justify future study, but emphasized well-designed clinical trials lacking [25]
• Interpretation caution: Claims pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25]
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence profile: Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27]
• Bottom line: One of more interesting terpene research targets in this list, but remains far from clinically settled [27]

Terpinolene

• Evidence profile: One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research limits and interpretation

• Evidence base highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29]
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but that also means claims around them often become inflated
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14]
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12]

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17]
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23]
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29]
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12]
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11]

Practical takeaways for the formulas in this document

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild ingredient; is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (Limonene, Myrcene, Caryophyllene, Pinene, Linalool, Humulene, Terpinolene)
• Format: 30mL bottle with graduated dropper (0.1mL increments)
• Active cannabinoids per mL: 553mg
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximate doses per bottle: 40-60 depending on serving size
• Price: $129.99

For Mitchell County makers: This is your open-source recipe. Source these exact cannabinoid distillates and isolates, combine in these ratios with organic MCT oil and 5% live terpenes, and you’ll create an equivalent product. We publish this because Rick Simpson taught people to make their own, and we honor that tradition.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• 510-thread universal battery compatibility
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Price: $49.99

For Mitchell County vapers: The 510-thread compatibility means this works with standard vape batteries available at any smoke shop in Kansas. The vape format auto-decarboxylates THCa at 400-450°F, delivering instant relief.

TERPENE PROFILE (Both Products)

Our seven-terpene profile is identical across both RSO formats:

• Limonene — Citrus-bright, mood-lifting
• Myrcene — Herbal, relaxing
• Caryophyllene (β-caryophyllene) — Pepper/spice, CB2 activation
• Pinene — Forest-fresh, clarity
• Linalool — Floral/lavender, calming
• Humulene — Earthy/woody, anti-inflammatory
• Terpinolene — Piney/fruity, sparkling complexity

For Kansas residents familiar with aromatherapy or essential oils: These terpenes are the same compounds found in citrus peels, pine forests, lavender fields, and black pepper. If you’ve used essential oils for wellness, you’re already familiar with these molecules. We’ve simply included them in therapeutic ratios alongside cannabinoids.

FINAL THOUGHTS FOR MITCHELL COUNTY

Rick Simpson started a movement when he gave his oil away for free to cancer patients in Nova Scotia. He taught people to make their own, refused to patent anything, and never charged the sick. That was the original RSO ethos.

OilWell Cannabis honors that origin by doing something no other company does: we sell a professionally manufactured, lab-tested, standardized RSO product and we publish the complete formula so you can make your own if you choose. We operate legally under the Farm Bill, ship nationwide to Kansas, and put potency control entirely in your hands through THCa chemistry.

Our story began when a paralyzed dog named Bentley got up and brought his ball to play. It continued through Colin’s personal battle with PTSD and benzo addiction. It evolved through seven ABC13 features where we chose honesty over hype, community action over profit, and transparency over trade secrets. It’s grown into the most comprehensive, evidence-based RSO resource available — one that refuses to overstate what the science shows and refuses to hide what it doesn’t.

For Mitchell County residents searching for answers: Whether you’re in Beloit dealing with chronic pain from decades of agricultural work, in Cawker City supporting a family member through cancer treatment, in Tipton managing PTSD, or anywhere in our rural Kansas communities just trying to sleep through the night — you deserve honest information. You deserve products made with intent. You deserve the ability to control your own medicine.

This is what we offer. No snake oil. No false hope. Just real formulas, real research, real transparency, and a real commitment to the mission that started when Bentley got up.

Order today at oilwellcbd.com — we ship directly to Mitchell County, Kansas.

Questions? Call (832) 416-2816 or email [email protected]. We’re here to help Mitchell County residents make informed decisions.

Legal disclaimers and age requirements: All products are for adults age 21+ only. Products contain less than 0.3% delta-9 THC by dry weight and are Farm Bill compliant. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before use. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Buyer assumes responsibility for compliance with Kansas laws. Keep out of reach of children. Use responsibly.